Press Room (Product News) https://stage.mediaroom.com/sanofi/ MediaRoom Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease https://stage.mediaroom.com/sanofi/press-releases?item=137335 Dupixent 300 mg weekly significantly improved the ability to swallow and reduced eosinophils in the esophagus compared to placebo, reinforcing positive results from first Phase 3 trial Mon, 25 Oct 2021 01:00:00 -0400 https://stage.mediaroom.com/sanofi/press-releases?item=137335 Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease https://stage.mediaroom.com/sanofi/2021-10-22-Dupixent-R-dupilumab-is-the-first-biologic-to-significantly-reduce-itch-and-skin-lesions-in-Phase-3-trial-for-prurigo-nodularis,-demonstrating-the-role-of-type-2-inflammation-in-this-disease Pivotal trial met primary and all key secondary endpoints Fri, 22 Oct 2021 01:05:00 -0400 https://stage.mediaroom.com/sanofi/2021-10-22-Dupixent-R-dupilumab-is-the-first-biologic-to-significantly-reduce-itch-and-skin-lesions-in-Phase-3-trial-for-prurigo-nodularis,-demonstrating-the-role-of-type-2-inflammation-in-this-disease FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma https://stage.mediaroom.com/sanofi/2021-10-20-FDA-expands-approval-of-Dupixent-R-dupilumab-to-include-children-aged-6-to-11-years-with-moderate-to-severe-asthma Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option Wed, 20 Oct 2021 17:30:00 -0400 https://stage.mediaroom.com/sanofi/2021-10-20-FDA-expands-approval-of-Dupixent-R-dupilumab-to-include-children-aged-6-to-11-years-with-moderate-to-severe-asthma Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months https://stage.mediaroom.com/sanofi/press-releases?item=137328 Dupixent rapidly improved symptoms after first dose, improving itch in one week and skin clearance in two weeks Mon, 30 Aug 2021 01:05:00 -0400 https://stage.mediaroom.com/sanofi/press-releases?item=137328 FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease https://stage.mediaroom.com/sanofi/2021-08-06-FDA-approves-Nexviazyme-R-avalglucosidase-alfa-ngpt-,-an-important-new-treatment-option-for-late-onset-Pompe-disease Approval is based on positive Phase 3 data demonstrating improvements in key disease burden measures and establishing its safety profile Fri, 06 Aug 2021 12:28:00 -0400 https://stage.mediaroom.com/sanofi/2021-08-06-FDA-approves-Nexviazyme-R-avalglucosidase-alfa-ngpt-,-an-important-new-treatment-option-for-late-onset-Pompe-disease